Inactive Instrument

ValiRx Plc Share Price London S.E.

Equities

GB00B23N9136

Biotechnology & Medical Research

End-of-day quote London S.E.
- GBX - Intraday chart for ValiRx Plc
Sales 2022 - Sales 2023 0.01 0.8 Capitalization 6.04M 504M
Net income 2022 -2M -167M Net income 2023 -2M -167M EV / Sales 2022 -
Net cash position 2022 1.1M 91.84M Net cash position 2023 153K 12.75M EV / Sales 2023 61,29,41,875 x
P/E ratio 2022
-4.57 x
P/E ratio 2023
-2.94 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 83.16%
More Fundamentals * Assessed data
Managers TitleAgeSince
Chief Executive Officer 46 -
Director of Finance/CFO 79 01/06/01
Chief Tech/Sci/R&D Officer - 08/22/08
Members of the board TitleAgeSince
Director of Finance/CFO 79 01/06/01
Director/Board Member 57 22/04
Chief Executive Officer 46 -
More insiders
ValiRx plc is a life science company. The Company is focused on early-stage cancer therapeutics and women's health. The Company provides the scientific, financial and commercial framework to enable the rapid translation of science into clinical development. Its product pipeline includes VAL201, VAL301, VAL401 and BC201. VAL201 is a short peptide being studied for the treatment of prostate cancer. VAL201 can prevent cancerous cell proliferation (or growth) without interfering with other functions of the androgen receptor or SRC kinase. Its VAL301 for the treatment of women with endometriosis. BC201 is a combination of the peptide ingredient of VAL201/VAL301 with active components to dampen this excessive immune response and consequently improve severe symptoms of Covid-19. It operates through divisional companies, including ValiPharma, ValiSeek, Cytolytix Limited, and Inaphaea BioLabs Limited.
More about the company